5-(4-chlorobenzyl)thiophene-2-carbaldehyde | 101336-12-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(4-chlorobenzyl)thiophene-2-carbaldehyde
• 英文别名: 5-[(4-chlorophenyl)methyl]thiophene-2-carbaldehyde
• CAS: 101336-12-3
• 化学式: C₁₂H₉ClOS
• 分子量: 236.722
• InChiKey: PCVIGYOOZPUNSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  45.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-(4-chlorobenzyl)thiophene-2-carbaldehyde 在 sodium tetrahydroborate 、 potassium permanganate 、 磺酰氯 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Cu(II)-Promoted Transformations of α-Thienylcarbinols into Spirothienooxindoles: Regioselective Halogenation of Dienyl Sulfethers Containing Electron-Rich Aryl Rings

  摘要：

  Under the promotion of Cu(II) salts, the alpha-thienylcarbinols with an N-phenyl carbonyl group at the other alpha-position are converted into three different ranges of spirothienooxindoles involving dearomatizing Friedel-Crafts reaction. In addition, the unprecedented regioselective CuX2-mediated C-H functionalization/halogenation of dienyl sulfether containing electron-rich aryl rings is presented.

  DOI：

  10.1021/jo301039y
• 作为产物：
  描述：

  N,N-二甲基甲酰胺 、 2-(4-chlorobenzyl)thiophene 在 三氯氧磷 作用下， 以 二氯甲烷 为溶剂， 生成 5-(4-chlorobenzyl)thiophene-2-carbaldehyde
  参考文献：
  名称：

  Cu(II)-Promoted Transformations of α-Thienylcarbinols into Spirothienooxindoles: Regioselective Halogenation of Dienyl Sulfethers Containing Electron-Rich Aryl Rings

  摘要：

  Under the promotion of Cu(II) salts, the alpha-thienylcarbinols with an N-phenyl carbonyl group at the other alpha-position are converted into three different ranges of spirothienooxindoles involving dearomatizing Friedel-Crafts reaction. In addition, the unprecedented regioselective CuX2-mediated C-H functionalization/halogenation of dienyl sulfether containing electron-rich aryl rings is presented.

  DOI：

  10.1021/jo301039y
• 作为试剂：
  描述：

  5-醛基-2-噻吩硼酸 、 4-chlorobenzyl diethyl phosphate 、 4-(4-氯苄基)噻吩-2-甲醛 在 5-(4-chlorobenzyl)thiophene-2-carbaldehyde 、 ethyl acetate heptane 作用下， 以yielded 5-(4-chlorobenzyl)thiophene-2-carbaldehyde (730 mg, 48%)的产率得到5-(4-chlorobenzyl)thiophene-2-carbaldehyde
  参考文献：
  名称：

  FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE

  摘要：

  本发明提供了新型D-氨基酸氧化酶抑制剂，以及包括该发明化合物的制药组合物。本发明还提供了治疗和预防神经系统疾病，如神经精神疾病和神经退行性疾病，以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构：其中A为NH或S，Q为从CR1和N中选择的成员，X和Y是独立选择的成员，选择自O、S、CR2、N和NH。R1、R2和R4是独立选择的成员，选择自H和F，但至少选择R1、R2和R4中的一个成员为F。R6为从O-X+和OH中选择的成员，其中X+为正离子，选择自无机正离子和有机正离子。

  公开号：

  US20080004327A1

文献信息

• [EN] CYANOTRIAZOLE COMPOUNDS<br/>[FR] COMPOSÉS CYANOTRIAZOLE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2015008872A1

  公开（公告）日：2015-01-22

  This invention relates to a cyanotriazole compound represented by the formula (1):, wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖，副作用较少，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病，糖耐量受损，胰岛素抵抗，糖尿病并发症，肥胖，血脂异常，肝脂肪变性，动脉粥样硬化和/或心血管疾病，以及那些受益于刺激能量消耗的疾病或疾病。
• Omega-aryl-alkylthienyl-compounds and process for the treatment of
  申请人：A. Nattermann & CIE GmbH

  公开号：US04705802A1

  公开（公告）日：1987-11-10

  The invention relates to new .omega.-aryl-alkylthienyl compounds having the Formula I ##STR1## i.e. omega-aryl-alkyl thienyl alkanoic acids and, respectively, omega-aryl-alkyl thienyl alkenoic acids, the alkali metal salts of such acids and certain esters thereof. The invention further relates to processes for the treatment of chronically inflammatory processes in humans.

  本发明涉及具有以下式子I的新型ω-芳基-烷基噻吩化合物：##STR1## 即ω-芳基-烷基噻吩烷酸和ω-芳基-烷基噻吩烯酸，这些酸的碱金属盐以及某些酯。本发明还涉及用于治疗人类慢性炎症过程的方法。
• Fused heterocyclic inhibitors of D-amino acid oxidase
  申请人：Heffernan L. R. Michele

  公开号：US20080058395A1

  公开（公告）日：2008-03-06

  This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. Also provided are methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein Q is a member selected from O, S, CR 1 and N, X and Y are members independently selected from CR 2 , O, S, N and NR 3 .

  本发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括该发明化合物的制药组合物。同时，还提供了治疗和预防神经系统疾病，如神经精神疾病和神经退行性疾病，以及疼痛、共济失调和惊厥的方法。该发明化合物具有以下一般结构：其中Q是从O、S、CR1和N中选择的成员，X和Y是独立选择自CR2、O、S、N和NR3的成员。
• Fluoro-substituted inhibitors of D-amino acid oxidase
  申请人：Sepracor Inc.

  公开号：US07884124B2

  公开（公告）日：2011-02-08

  This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR1 and N. X and Y are members independently selected from O, S, CR2, N and NH. R1, R2 and R4 are members independently selected from H and F, provided that at least one member selected from R1, R2 and R4 is F. R6 is a member selected from O−X+ and OH, wherein X+ is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

  本发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括本发明化合物的制药组合物。本发明还提供了用于治疗和预防神经系统疾病，如神经精神疾病和神经退行性疾病，以及疼痛、共济失调和抽搐的方法。本发明化合物具有以下一般结构： 其中A为NH或S。Q为选择自CR1和N的成员。X和Y是独立选择自O、S、CR2、N和NH的成员。R1、R2和R4是独立选择自H和F的成员，但至少选择自R1、R2和R4中的一个成员为F。R6为选择自O−X+和OH的成员，其中X+为正离子，其为选择自无机正离子和有机正离子的成员。
• CYANOTRIAZOLE COMPOUNDS
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：US20160229816A1

  公开（公告）日：2016-08-11

  This invention relates to a cyanotriazole compound represented by the formula (1): wherein each symbols are defined in the specification, or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.

  本发明涉及一种由式（1）表示的氰基三唑化合物，其中每个符号在规范中有定义，或其盐。该化合物或其盐刺激柠檬酸循环活性和/或改善高血糖症的副作用较小，安全性优异，因此，它对于治疗和/或预防柠檬酸循环激活和/或改善高血糖症具有预防和/或治疗作用的疾病或疾病具有用处，例如糖尿病、糖耐量受损、胰岛素抵抗、糖尿病并发症、肥胖症、血脂异常、脂肪肝、动脉粥样硬化和/或心血管疾病，以及那些从刺激能量消耗中受益的疾病或疾病。